Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN (ZOMIG 311C90) HAS NO CLINICALLY SIGNIFICANT INTERACTIONS WITH PARACETAMOL OR METOCLOPRAMIDE
Autore:
SEABER EJ; RIDOUT G; LAYTON G; POSNER J; PECK RW;
Indirizzi:
GLAXO WELLCOME RES & DEV LTD,GREENFORD RD GREENFORD UB6 0HE MIDDX ENGLAND
Titolo Testata:
European Journal of Clinical Pharmacology
fascicolo: 3-4, volume: 53, anno: 1997,
pagine: 229 - 234
SICI:
0031-6970(1997)53:3-4<229:TNACZ(>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
SUMATRIPTAN; ABSORPTION; VOLUNTEERS; HEADACHE; AGONIST;
Keywords:
ZOLMITRIPTAN; MIGRAINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
E.J. Seaber et al., "THE NOVEL ANTIMIGRAINE COMPOUND ZOLMITRIPTAN (ZOMIG 311C90) HAS NO CLINICALLY SIGNIFICANT INTERACTIONS WITH PARACETAMOL OR METOCLOPRAMIDE", European Journal of Clinical Pharmacology, 53(3-4), 1997, pp. 229-234

Abstract

Objective: This study investigated potential pharmacokinetic or pharmacodynamic interactions between the novel anti-migraine compound zolmitriptan (Zomig, formerly 311C90) and paracetamol and/or metoclopramide. Methods: In an open-label, randomised, crossover study, 15 healthy volunteers received single oral doses of 10 mg zolmitriptan alone, 1 g paracetamol alone, 10 mg zolmitriptan + 1 g paracetamol, 10 mg zolmitriptan + 10 mg metoclopramide or 10 mg zolmitriptan + 1 g paracetamol 10 mg metoclopramide on five separate occasions. Results: Metoclopramide had no significant effects on the pharmacokinetics of zolmitriptanor the active zolmitriptan metabolite 183C91, nor did it affect interactions between zolmitriptan and paracetamol. Paracetamol marginally increased the maximum plasma concentration (C-max) (11%) and the area under the curve (AUG) (11%) and reduced the renal clearance of zolmitriptan (9%); similar small effects were seen on 183C91. The AUG, C-max and half-life of paracetamol were reduced by concomitant zolmitriptan (by 11%; 31% and 8%, respectively), whilst the mean residence time showed a small increase (+0.7 h). There was a trend towards a transient increase in blood pressure: following all regimens containing zolmitriptan; this effect was small, was consistent between all zolmitriptan regimens as well as with previous studies, and was considered to be clinically insignificant. Zolmitriptan was well tolerated after all treatment regimens. Conclusion: Concomitant administration of zolmitriptan and paracetamol resulted in a slight increase in bioavailability of zolmitriptan and a reduced rate and extent of paracetamol absorption. These findings are considered io be of no clinical significance and there is no reason to avoid concomitant administration of paracetamol and/ormetoclopramide with zolmitriptan.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/12/20 alle ore 20:58:58